Torrent Pharmaceuticals (NSE:TORNTPHARM) Piotroski F-Score: 6 (As of Jul. 01, 2026) — 14% Below Median


NSE:TORNTPHARM Torrent Pharmaceuticals Ltd NSE:TORNTPHARM
85 GF Score
Price ₹4,620.10
GF Value ₹4,314.31
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Torrent Pharmaceuticals Piotroski F-Score?

Torrent Pharmaceuticals NSE:TORNTPHARM -0.81% 85 Piotroski F-Score is 6 as of Jul. 01, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates NSE:TORNTPHARM with a GF Score™ of 85/100 and a GF Value™ of ₹4,314.31 (Fairly Valued). The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, Torrent Pharmaceuticals ranks better than 79.16% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Torrent Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Torrent Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

NSE:TORNTPHARM' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Torrent Pharmaceuticals was 9. The lowest was 5. And the median was 7.

Torrent Pharmaceuticals  (NSE:TORNTPHARM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Torrent Pharmaceuticals Piotroski F-Score Related Terms


Torrent Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Torrent Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Torrent Pharmaceuticals Piotroski F-Score Chart

Torrent Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 7.00 8.00 9.00 6.00

Torrent Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 0.00 0.00 0.00 6.00

NSE:TORNTPHARM vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Torrent Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Torrent Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torrent Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Torrent Pharmaceuticals's Piotroski F-Score falls into.


NSE:TORNTPHARM
85GF Score
Torrent Pharmaceuticals Ltd NSE:TORNTPHARM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹21,634 Mil.
Cash Flow from Operations was ₹30,227 Mil.
Revenue was ₹137,530 Mil.
Gross Profit was ₹102,279 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (149897.4 + 443119.6) / 2 = ₹296508.5 Mil.
Total Assets at the begining of this year (Mar25) was ₹149,897 Mil.
Long-Term Debt & Capital Lease Obligation was ₹118,412 Mil.
Total Current Assets was ₹93,919 Mil.
Total Current Liabilities was ₹83,433 Mil.
Net Income was ₹19,113 Mil.

Revenue was ₹113,173 Mil.
Gross Profit was ₹84,328 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (150605.8 + 149897.4) / 2 = ₹150251.6 Mil.
Total Assets at the begining of last year (Mar24) was ₹150,606 Mil.
Long-Term Debt & Capital Lease Obligation was ₹13,376 Mil.
Total Current Assets was ₹56,226 Mil.
Total Current Liabilities was ₹47,172 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Torrent Pharmaceuticals's current Net Income (TTM) was 21,634. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Torrent Pharmaceuticals's current Cash Flow from Operations (TTM) was 30,227. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=21633.7/149897.4
=0.14432338

ROA (Last Year)=Net Income/Total Assets (Mar24)
=19112.5/150605.8
=0.12690414

Torrent Pharmaceuticals's return on assets of this year was 0.14432338. Torrent Pharmaceuticals's return on assets of last year was 0.12690414. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Torrent Pharmaceuticals's current Net Income (TTM) was 21,634. Torrent Pharmaceuticals's current Cash Flow from Operations (TTM) was 30,227. ==> 30,227 > 21,634 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=118412.4/296508.5
=0.39935584

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=13376.1/150251.6
=0.08902468

Torrent Pharmaceuticals's gearing of this year was 0.39935584. Torrent Pharmaceuticals's gearing of last year was 0.08902468. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=93918.9/83433.3
=1.12567644

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=56225.7/47171.9
=1.19193206

Torrent Pharmaceuticals's current ratio of this year was 1.12567644. Torrent Pharmaceuticals's current ratio of last year was 1.19193206. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Torrent Pharmaceuticals's number of shares in issue this year was 338.445. Torrent Pharmaceuticals's number of shares in issue last year was 338.445. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=102278.8/137529.9
=0.7436841

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=84327.6/113172.5
=0.74512448

Torrent Pharmaceuticals's gross margin of this year was 0.7436841. Torrent Pharmaceuticals's gross margin of last year was 0.74512448. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=137529.9/149897.4
=0.91749357

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=113172.5/150605.8
=0.75144848

Torrent Pharmaceuticals's asset turnover of this year was 0.91749357. Torrent Pharmaceuticals's asset turnover of last year was 0.75144848. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Torrent Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Torrent Pharmaceuticals (NSE:TORNTPHARM) has a Piotroski F-Score of 6 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Torrent Pharmaceuticals and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Torrent Pharmaceuticals' Piotroski F-Score has ranged from 5.00 to 9.00. According to the industry distribution chart, Torrent Pharmaceuticals ranks #204 out of 979 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Torrent Pharmaceuticals' Piotroski F-Score too high?
Torrent Pharmaceuticals' current Piotroski F-Score of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Torrent Pharmaceuticals' value of 6 is 20% above this industry median. Based on the distribution chart, Torrent Pharmaceuticals ranks #204 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Torrent Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Torrent Pharmaceuticals' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Torrent Pharmaceuticals ranks #204 out of 979 companies for Piotroski F-Score. This places Torrent Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Torrent Pharmaceuticals' value of 6 is 20% above this benchmark. Historically, Torrent Pharmaceuticals' own Piotroski F-Score has ranged from 5.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Torrent Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Torrent Pharmaceuticals's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Torrent Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Torrent Pharmaceuticals's current Piotroski F-Score is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Torrent Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Torrent Pharmaceuticals (NSE:TORNTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹4,314.31, compared to a current price of ₹4,620.10 — trading 7.1% above its estimated fair value. The current Piotroski F-Score is 6, which is 14% below median its 10-year median of 7.00 and 20% above the Drug Manufacturers industry median of 5.00. Torrent Pharmaceuticals' overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Torrent Pharmaceuticals (NSE:TORNTPHARM), the current Piotroski F-Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Torrent Pharmaceuticals stock appears to be overvalued. The current stock price of ₹4,620.10 is trading 7.1% above its estimated GF Value™ of ₹4,314.31. GuruFocus considers Torrent Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:TORNTPHARM:

  • Piotroski F-Score: 6 (14% below median its 10-year median of 7.00)
  • GF Value™: ₹4,314.31 vs. price of ₹4,620.10 (7.1% above fair value)
  • GF Score™: 85/100 with 6 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#204 of 979)

No single metric tells the full story. See the NSE:TORNTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Torrent Pharmaceuticals Business Description

Other Exchanges 500420:India
Address Off Ashram Road, Torrent House, Ahmedabad, GJ, IND, 380009
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
85GF Score

Get the complete analysis for NSE:TORNTPHARM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,620.10
Price
₹4,314.31
GF Value